Drug Safety

, Volume 25, Issue 5, pp 345–372 | Cite as

Drug-Induced Cutaneous Photosensitivity

Incidence, Mechanism, Prevention and Management
Review Article

Abstract

The interaction of sunlight with drug medication leads to photosensitivity responses in susceptible patients, and has the potential to increase the incidence of skin cancer. Adverse photosensitivity responses to drugs occur predominantly as a phototoxic reaction which is more immediate than photoallergy, and can be reversed by withdrawal or substitution of the drug. The bias and inaccuracy of the reporting procedure for these adverse reactions is a consequence of the difficulty in distinguishing between sunburn and a mild drug photosensitivity reaction, together with the patient being able to control the incidence by taking protective action. The drug classes that currently are eliciting a high level of adverse photosensitivity are the diuretic, antibacterial and nonsteroidal anti-inflammatory drugs (NSAIDs). Photosensitising chemicals usually have a low molecular weight (200 to 500 Daltons) and are planar, tricyclic, or polycyclic configurations, often with heteroatoms in their structures enabling resonance stabilisation. All absorb ultraviolet (UV) and/or visible radiation, a characteristic that is essential for the chemical to be regarded as a photosensitiser. The photochemical and photobiological mechanisms underlying the adverse reactions caused by the more photoactive drugs are mainly free radical in nature, but reactive oxygen species are also involved. Drugs that contain chlorine substituents in their chemical structure, such as hydrochlorthiazide, furosemide and chlorpromazine, exhibit photochemical activity that is traced to the UV-induced dissociation of the chlorine substituent leading to free radical reactions with lipids, proteins and DNA. The photochemical mechanisms for the NSAIDs that contain the 2-aryl propionic acid group involve decarboxylation as the primary step, with subsequent free radical activity. In aerated systems, the reactive excited singlet form of oxygen is produced with high efficiency. This form of oxygen is highly reactive towards lipids and proteins. NSAIDs without the 2-arylpropionic acid group are also photoactive, but with differing mechanisms leading to a less severe biological outcome. In the antibacterial drug class, the tetracyclines, fluoroquinolones and sulfonamides are the most photoactive. Photocontact dermatitis due to topically applied agents interacting with sunlight has been reported for some sunscreen and cosmetic ingredients, as well as local anaesthetic and antiacne agents. Prevention of photosensitivity involves adequate protection from the sun with clothing and sunscreens. In concert with the preponderance of free radical mechanisms involving the photosensitising drugs, some recent studies suggest that diet supplementation with antioxidants may be beneficial in increasing the minimum erythemal UV radiation dose.

References

  1. 1.
    International Agency for Research on Cancer (IARC). Solar and ultraviolet radiation. IARC Monogr Eval Carcinog Risks Hum 1992; 55: 1–316Google Scholar
  2. 2.
    Marks R. Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: a tale of self-immolation in Elysian fields [review]. Australas J Dermatol 1997; 38Suppl. 1: S26–9PubMedGoogle Scholar
  3. 3.
    Rusonis ES, Rusonis PA, Miller C, et al. Skin cancer detection and prevention: a community program promoting sun safe behaviours. Md Med J 1999; 48(4): 169–72PubMedGoogle Scholar
  4. 4.
    Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies [review]. Cancer Causes Control 2001; 12(1): 69–82PubMedCrossRefGoogle Scholar
  5. 5.
    Jagger J. Solar-UV actions on living cells. New York: Praeger Scientific, 1985: 1–10Google Scholar
  6. 6.
    Loomis WF. Rickets. Sci Am 1970; 223(6): 76–82PubMedCrossRefGoogle Scholar
  7. 7.
    Parrish JA, Anderson RR, Urbach F, et al. UV-A: Biological effects of ultraviolet radiation with emphasis on human responses to longwave ultraviolet. New York: Plenum Press, 1978Google Scholar
  8. 8.
    Epstein JH. Photomedicine. In: Smith KC, editor. The science of photobiology. 2nd ed. New York: Plenum Press, 1989: 155–92CrossRefGoogle Scholar
  9. 9.
    Kocsard E. Solar keratoses and their relationship to non-melanoma skin cancers [review]. Australas J Dermatol 1997; 38Suppl. 1: S30PubMedGoogle Scholar
  10. 10.
    Russell DH. Ornithine decarboxylase: a key regulatory enzyme in normal and neoplastic growth. Drug Metab Rev 1985; 16: 1–88PubMedCrossRefGoogle Scholar
  11. 11.
    Dahlback A, Henriksen T, Larsen SHH, et al. Biological UV-doses and the effect of an ozone layer depletion. Photochem Photobiol 1989; 49: 621–5PubMedCrossRefGoogle Scholar
  12. 12.
    Sobolev I. Effect of column ozone on the variability of biologically effective UV radiation at high southern latitudes. Photochem Photobiol 2000; 72: 753–65PubMedCrossRefGoogle Scholar
  13. 13.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000; 356: 1255–9PubMedCrossRefGoogle Scholar
  14. 14.
    Baker CS. Photosensitivity. Med J Aust 1996; 165: 96–101PubMedGoogle Scholar
  15. 15.
    Epstein JH. Phototoxicity and photoallergy. Semin Cutan Med Surg 1999; 18: 274–84PubMedCrossRefGoogle Scholar
  16. 16.
    Dall’ Acqua F, Jori G. Photochemotherapy. In: Foye WO, Lemke TL, Williams DA, editors. Principles of medicinal chemistry. 4th ed. Baltimore: Williams and Wilkins, 1995: 893–907Google Scholar
  17. 17.
    Ackroyd R, Kelty C, Brown N, et al. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001; 74(5): 656–69PubMedCrossRefGoogle Scholar
  18. 18.
    Avalos J, Maibach HI, editors. Dermatologic botany. Boca Raton: CRC Press, 1999: 51–65Google Scholar
  19. 19.
    Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem Photobiol 1995; 61: 529–39PubMedCrossRefGoogle Scholar
  20. 20.
    Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33: 551–73PubMedCrossRefGoogle Scholar
  21. 21.
    Magnus IA. Dermatological photobiology. London: Blackwells, 1976: 213–215Google Scholar
  22. 22.
    Australian Department of Health. Adverse Drug Reactions Advisory Committee (ADRAC). A sunburnt country. Adverse Drug Reactions Bulletin. Canberra, Mar 1983, Feb 1987Google Scholar
  23. 23.
    Harth Y, Rapoport M. Phototoxicity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996; 14: 252–9PubMedCrossRefGoogle Scholar
  24. 24.
    Wainwright NJ, Collins P, Ferguson J. Photosensitivity associated with antibacterial agents. Drug Saf 1993; 9: 437–40PubMedCrossRefGoogle Scholar
  25. 25.
    Mammen L, Schmidt CP. Photosensitivity reactions: a case report involving NSAIDs. Am Fam Physician 1995; 52: 575–9PubMedGoogle Scholar
  26. 26.
    Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 14th ed. Amsterdam: Elsevier, 2000Google Scholar
  27. 27.
    Litt JZ. Drug eruption reference manual 2000. New York: Parthenon, 2000, The Pharmacists guide to drug eruptions and interactionsGoogle Scholar
  28. 28.
    Cooper SM, George S. Photosensitivity reaction associated with use of the combined oral contraceptive. Br J Dermatol 2001: 144, 641–2PubMedCrossRefGoogle Scholar
  29. 29.
    Schoonderwoerd SA, Beiersbergen van Henegouwen GMJ, Luijendijk HJ. Photobinding of chlorpromazine and its sulfoxide in vitro and in vivo. Photochem Photobiol 1988; 48: 621–6PubMedCrossRefGoogle Scholar
  30. 30.
    Western A, Van Camp JR, Bensasson R, et al. Involvement of singlet oxygen in the phototoxicity for a metabolite of piroxicam. Photochem Photobiol 1987; 46: 469–75PubMedCrossRefGoogle Scholar
  31. 31.
    Kelly GE, Meikle WD, Moore DE. Promotion of UV-induced skin carcinogenesis by azathioprine: role of photochemical sensitization. Photochem Photobiol 1989; 49: 59–65PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson BE, Gibbs NK, Ferguson J. Quinolone antibiotic with potential to photosensitise skin tumorigenesis. J Photochem Photobiol B 1997; 37: 171–3PubMedCrossRefGoogle Scholar
  33. 33.
    Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759–64PubMedCrossRefGoogle Scholar
  34. 34.
    Sheil AGR. Cancer in dialysis and transplant patients. In: Morris PJ, editor. Kidney transplantation. 2nd ed. London: Grune and Stratton, 1984: 491–507Google Scholar
  35. 35.
    Monk B. Amiodarone-induced photosensitivity and basal cell carcinoma. Clin Exp Dermatol 1990; 15: 319–20PubMedCrossRefGoogle Scholar
  36. 36.
    Monk B. Basal cell carcinoma following amiodarone therapy. Br J Dermatol 1995; 133: 148–9PubMedCrossRefGoogle Scholar
  37. 37.
    Beiersbergen van Henegouwen GMJ. The interference of light in pharmacotherapy. Pharm Weekblad Sci 1981; 3: 85–95Google Scholar
  38. 38.
    Miranda MA. Assessment of the phototoxicity risk of new drugs. In: Seiler JP, Vilanova E, editors. Applied toxicology: approaches through basic science. Berlin: Springer-Verlag, 1997: 249–58CrossRefGoogle Scholar
  39. 39.
    Moore DE. Mechanisms of photosensitization by phototoxic drugs. Mutat Res 1998; 422: 165–73PubMedCrossRefGoogle Scholar
  40. 40.
    Bensasson RV, Land EJ, Truscott TG. Flash photolysis and pulse radiolysis. Oxford: Pergamon Press, 1983: 1–19Google Scholar
  41. 41.
    Spikes JD. Photosensitization. In: Smith KC, editor. The science of photobiology. 2nd ed. New York: Plenum, 1989: 79–110CrossRefGoogle Scholar
  42. 42.
    Moore DE. Photophysical and photochemical aspects of drug stability. In: Tonnesen HH, editor. Photostability of drugs and drug formulations. London: Taylor and Francis, 1996: 9–38Google Scholar
  43. 43.
    Moore DE, Zhou W. Photodegradation of sulfamethoxazole: a chemical system capable of monitoring seasonal changes in UVB intensity. Photochem Photobiol 1994; 59: 497–502PubMedCrossRefGoogle Scholar
  44. 44.
    Davies AK, Navaratnam S, Phillips GO. Photochemistry of chlorpromazine (2-chloro-N-(3-dimethylaminopropyl)phenothiazine) in propan-2-ol solution. J Chem Soc [Perkin] 1976; 2: 25–9Google Scholar
  45. 45.
    Tamat SR, Moore DE. Photolytic decomposition of hydrochlorothiazide. J Pharm Sci 1983; 72: 180–3PubMedCrossRefGoogle Scholar
  46. 46.
    Moore DE, Hemmens VJ. Photosensitization by antimalarial drugs. Photochem Photobiol 1982; 36: 71–7PubMedCrossRefGoogle Scholar
  47. 47.
    Moore DE, Sithipitaks V. Photolytic degradation of frusemide. J Pharm Pharmacol 1983; 35: 489–93PubMedCrossRefGoogle Scholar
  48. 48.
    Moore DE, Roberts-Thomson S, Dong Z, et al. Photochemical studies on the anti-inflammatory drug diclofenac. Photochem Photobiol 1990; 52: 685–90PubMedCrossRefGoogle Scholar
  49. 49.
    Li YNB, Moore DE, Tattam BN. Photodegradation of amiloride in aqueous solution. Int J Pharm 1999; 183: 109–16PubMedCrossRefGoogle Scholar
  50. 50.
    Grimshaw J, de Silva AP. Photochemistry and photocyclization of aryl halides. Chem Soc Rev 1981; 10: 181–203CrossRefGoogle Scholar
  51. 51.
    Davies AK, Hilal NS, McKellar JF, et al. Photochemistry of tetrachlorosalicylanilide and its relevance to the persistent light reactor. Br J Dermatol 1975; 92: 143–7PubMedCrossRefGoogle Scholar
  52. 52.
    Cornelissen PJG, Beijersbergen Van Henegouwen GMJ, Gerritsma KW. Photochemical decomposition of 1,4-benzodiazepines. Chlordiazepoxide. Int J Pharm 1979; 3: 205–20CrossRefGoogle Scholar
  53. 53.
    Beiersbergen van Henegouwen GMJ. Systemic phototoxicity of drugs and other xenobiotics. J Photochem Photobiol B 1991; 10: 183–210CrossRefGoogle Scholar
  54. 54.
    Gorman AA, Rodgers MAJ. Singlet molecular oxygen. Chem Soc Rev 1981; 10: 205–31CrossRefGoogle Scholar
  55. 55.
    Matheson ICB, Lee J. Chemical reaction rates of amino acids with singlet oxygen. Photochem Photobiol 1979; 29: 879–81CrossRefGoogle Scholar
  56. 56.
    Cadet J, Berger M, Douki T, et al. Oxidative damage to DNA: formation, measurement and biological significance. Rev Physiol Biochem Pharmacol 1997; 31: 1–87Google Scholar
  57. 57.
    Kochevar IE, Garcia C, Geacintov NE. Photoaddition to DNA by nonintercalated chlorpromazine molecules. Photochem Photobiol 1998; 68: 692–7PubMedCrossRefGoogle Scholar
  58. 58.
    Kochevar IE. Phototoxicity of non-steroidal anti-inflammatory drugs: coincidence or specific mechanism? Arch Dermatol 1989; 125: 824–6CrossRefGoogle Scholar
  59. 59.
    Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1–10PubMedCrossRefGoogle Scholar
  60. 60.
    Moore DE, Chappuis PP. A comparative study of the photochemistry of the non-steroidal anti-inflammatory drugs, naproxen, benoxaprofen and indomethacin. Photochem Photobiol 1988; 47: 173–81PubMedCrossRefGoogle Scholar
  61. 61.
    Costanzo LL, De Guidi G, Condorelli G, et al. Molecular mechanism of naproxen photosensitization in red blood cells. J Photochem Photobiol B 1989; 3: 223–5PubMedCrossRefGoogle Scholar
  62. 62.
    Bosca F, Miranda MA, Vano L, et al. New photodegradation pathways of naproxen, a phototoxic non-steroidal antiinflammatory drug. J Photochem Photobiol A - Chemistry 1990; 54: 131–4CrossRefGoogle Scholar
  63. 63.
    Bosca F, Miranda MA, Carganico G, et al. Photochemical and photobiological properties of ketoprofen associated with the benzophenone chromophore. Photochem Photobiol 1994; 60: 96–101PubMedCrossRefGoogle Scholar
  64. 64.
    Monti S, Sortino S, De Guidi G, et al. Photochemistry of 2-(3-benzoylphenyl)-propionic acid (ketoprofen). Pt 1. A picosecond and nanasecond time resolved study in aqueous solution. J Chem Soc Faraday Trans 1997; 93: 2269–75CrossRefGoogle Scholar
  65. 65.
    Castell JV, Gomez-Lechon ML, Miranda MA, et al. Photolytic degradation of ibuprofen: toxicity of the isolated photoproducts on fibroblasts and erythrocytes. Photochem Photobiol 1987; 46: 991–6PubMedCrossRefGoogle Scholar
  66. 66.
    Costanzo LL, De Guidi G, Condorelli G, et al. Molecular mechanism of drug photosensitization-II. Photohemolysis sensitized by ketoprofen. Photochem Photobiol 1989; 50: 359–65PubMedCrossRefGoogle Scholar
  67. 67.
    De la Pena D, Marti C, Nonell S, et al. Time-resolved near infrared studies on singlet oxygen production by the photosensitizing 2-arylpropionic acids. Photochem Photobiol 1997; 65: 828–32CrossRefGoogle Scholar
  68. 68.
    Halliwell B, Gutteridge JM. Free radicals in biology and medicine. 3rd ed. Oxford: Oxford University Press, 1999: 544–616, 784-859Google Scholar
  69. 69.
    Castell JV, Hernandez D, Gomez-Lechon MJ, et al. Photobinding of tiaprofenic acid and suprofen to proteins and cells. Photochem Photobiol 1998; 68: 660–5PubMedCrossRefGoogle Scholar
  70. 70.
    Marguery MC, Chouini-Lalanne N, Ader JC, et al. Comparison of the DNA damage photoinduced by fenofibrate and ketoprofen, two phototoxic drugs of parent structure. Photochem Photobiol 1998; 68: 679–84PubMedCrossRefGoogle Scholar
  71. 71.
    Moore DE, Ghebremeskel KA, Chen BBC, et al. Electron transfer processes in the reactivity of nonsteroidal anti-inflammatory drugs in the ground and excited states. Photochem Photobiol 1998; 68: 685–91PubMedCrossRefGoogle Scholar
  72. 72.
    Stern RS, Bigby M. An expanded profile of cutaneous reactions to non-steroidal anti-inflammatory drugs. JAMA 1984; 252: 1433–7PubMedCrossRefGoogle Scholar
  73. 73.
    Becker RS, Chakravorti S, Yoon M. Photochemical and photophysical properties of piroxicam and benoxaprofen in various solvents. Photochem Photobiol 1990; 51: 151–4PubMedCrossRefGoogle Scholar
  74. 74.
    Miranda M, Vargas F, Serrano G. Photodegradation of piroxicam under aerobic conditions: the photochemical keys of the piroxicam enigma? J Photochem Photobiol B 1991; 8: 199–202PubMedCrossRefGoogle Scholar
  75. 75.
    Ljunggren B. Propionic acid-derived non-steroidal anti-inflammatory drugs are phototoxic in vitro. Photodermatol 1985; 2: 3–9PubMedGoogle Scholar
  76. 76.
    Ljunggren B, Lundberg K. In vivo phototoxicity of non-steroidal anti-inflammatory drugs evaluated by the mouse tail technique. Photodermatol 1985; 2: 377–82PubMedGoogle Scholar
  77. 77.
    Dabestani R, Sik RH, Davies DG, et al. Spectroscopic studies of cutaneous photosensitizing agents. XVIII. Indomethacin. Photochem Photobiol 1993; 58: 367–73PubMedCrossRefGoogle Scholar
  78. 78.
    Pawelczyk E, Knitter B. Kinetics of indomethacin degradation. Pharmazie 1977; 32: 698–9PubMedGoogle Scholar
  79. 79.
    Weedon AC, Wong DF. The photochemistry of indomethacin. J Photochem Photobiol - A Chem 1991; 61: 27–33CrossRefGoogle Scholar
  80. 80.
    Lim HW, Thorbecke GJ, Baer RL, et al. Effect of indomethacin on alteration of ATPase-positive Langerhans cell density and cutaneous sunburn reaction induced by ultraviolet-B radiation. J Invest Dermatol 1983; 81: 455–8PubMedCrossRefGoogle Scholar
  81. 81.
    Schwartz T, Gschnait F, Greiter F. Photoprotective effect of topical indomethacin - an experimental study. Dermatologica 1985; 171: 450–8CrossRefGoogle Scholar
  82. 82.
    Ikemura I. Contact and photocontact dermatitis due to benzydamine hydrochloride [letter]. Japanese J Clin Dermatol 1971; 25: 129Google Scholar
  83. 83.
    Fernandez De Corres L. Photodermatitis from benzydamine. Contact Dermatitis 1980; 6: 285–303CrossRefGoogle Scholar
  84. 84.
    Balato N, Lembo G, Patruno C, et al. Contact dermatitis from benzydamine hydrochloride [letter]. Contact Dermatitis 1986; 15: 105PubMedCrossRefGoogle Scholar
  85. 85.
    Bruynzeel DP. Contact allergy to benzydamine. Contact Dermatitis 1986; 14: 313–4PubMedCrossRefGoogle Scholar
  86. 86.
    Motley RJ, Reynolds AJ. Photodermatitis from benzydamine cream [letter]. Contact Dermatitis 1988; 19: 66PubMedCrossRefGoogle Scholar
  87. 87.
    Foti C, Vena GA, Angelini G. Occupational contact allergy to benzydamine hydrochloride. Contact Dermatitis 1992; 27: 328–9PubMedCrossRefGoogle Scholar
  88. 88.
    Goday BJJ, Ilardia LR, Soloeta AR. Allergic contact dermatitis from benzydamine with probable cross-reaction to indomethacin. Contact Dermatitis 1993; 28: 111–2CrossRefGoogle Scholar
  89. 89.
    Wang J, Moore DE. A study of the photodegradation of benzydamine in pharmaceutical formulations. J Pharm Biomed Anal 1992; 7: 535–40CrossRefGoogle Scholar
  90. 90.
    Moore DE, Wang J. Electron transfer mechanisms in photosensitization by the anti-inflammatory drug benzydamine. J Photochem Photobiol B 1998; 43: 175–80PubMedCrossRefGoogle Scholar
  91. 91.
    Nielson OH. Sulfasalazine intolerance: a retrospective survey of use in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1982; 17: 389–93CrossRefGoogle Scholar
  92. 92.
    Wiebe JA, Moore DE. Oxidation photosensitized by tetracyclines. J Pharm Sci 1977; 66: 186–9PubMedCrossRefGoogle Scholar
  93. 93.
    Moore DE, Fallon MP, Burt CD. Photo-oxidation of tetracycline - a differential pulse polarographic study. Int J Pharm 1983; 14: 133–42CrossRefGoogle Scholar
  94. 94.
    Ferguson J. Fluoroquinolone photosensitization: a review of clinical and laboratory studies. Photochem Photobiol 1995; 62: 954–8CrossRefGoogle Scholar
  95. 95.
    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13: 343–58PubMedCrossRefGoogle Scholar
  96. 96.
    Fasani E, Profumo A, Albini A. Photochem photobiol 1998; 68: 666–74PubMedCrossRefGoogle Scholar
  97. 97.
    Martinez LJ, Sik RH, Chignell CF. Fluoroquinolone antimicrobials: singlet oxygen, superoxide and phototoxicity. Photochem Photobiol 1998; 67: 399–403PubMedGoogle Scholar
  98. 98.
    Berger TG, Dhar A. Lichenoid photoeruptions in human immunodeficiency virus infection. Arch Dermatol 1994; 130: 609–13PubMedCrossRefGoogle Scholar
  99. 99.
    Zhou W, Moore DE. Photochemical decomposition of sulfamethoxazole. Int J Pharm 1994; 110: 55–63CrossRefGoogle Scholar
  100. 100.
    Bergh JJ, Breytenbach JC, Wessels PL. Degradation of trimethoprim. J Pharm Sci 1989; 78: 348–50PubMedCrossRefGoogle Scholar
  101. 101.
    Zhou W, Moore DE. Photosensitizing activity of the antibacterial drugs sulfamethoxazole and trimethoprim. Photochem Photobiol 1997; 39: 63–72CrossRefGoogle Scholar
  102. 102.
    Moore DE, Burt CD. Photosensitization by drugs in surfactant solutions. Photochem Photobiol 1981; 34: 431–9Google Scholar
  103. 103.
    Miranda MA, Castell JV, Gómez-Lechón MJ, et al. In vitro photoperoxidation as an indicator of the potential phototoxicity of non-steroidal anti-inflammatory 2-arylpropionic acids. Toxicol In Vitro 1993; 7: 523–6PubMedCrossRefGoogle Scholar
  104. 104.
    de Leo VA, Harber LC. Contact photodermatitis. In: Fisher AA, editor. Contact dermatitis. 3rd ed. Philadelphia (PA): Lee and Febiger, 1986: 454–69Google Scholar
  105. 105.
    Funk JO, Dromgoole SH, Maibach HI. Contact sensitisation and photocontact sensitisation of sunscreening agents. In: Lowe NJ, Shaath NA, Pathak MA, editors. Sunscreens. 2nd ed. New York: Dekker, 1997: 631–53Google Scholar
  106. 106.
    Fairhurst D, Mitchnick MA. Particulate sun blocks: general principals. In: Lowe NJ, Shaath NA, Pathak MA, editors. Sunscreens. 2nd ed. New York: Dekker, 1997: 313–51Google Scholar
  107. 107.
    Epstein JH. Adverse cutaneous reactions to the sun. In: Malkinson FD, Pearson RW, editors. Year book of dermatology. Chicago: Year Book Medical Publishers, 1971: 5–43Google Scholar
  108. 108.
    Standards Australia/Standards New Zealand. Sunscreen products - evaluation and classification. Sydney/Wellington, 1993. Report no. AS 2604Google Scholar
  109. 109.
    Gies PH, Roy CR, Toomey S, et al. Protection against solar ultraviolet radiation. Mutat Res 1998; 422: 15–22PubMedCrossRefGoogle Scholar
  110. 110.
    Reeve VE, Bosnic M, Boehm-Wilcox C, et al. Differential protection by two sunscreens from UV radiation-induced immunosuppression. J Invest Dermatol 1991; 97: 624–8PubMedCrossRefGoogle Scholar
  111. 111.
    Wolf P, Donawho CK, Kripke ML. Effect of sunscreens on UV radiation-induced enhancement of melanoma growth inmice. J Natl Cancer Inst 1994; 86: 99–105PubMedCrossRefGoogle Scholar
  112. 112.
    Serre I, Cano JP, Picot MC, et al. Immunosuppression induced by acute solar-simulated ultraviolet exposure in humans: prevention by a sunscreen with SPF 15 and high UVA protection. J Am Acad Dermatol 1997; 37: 187–94PubMedCrossRefGoogle Scholar
  113. 113.
    Cuzzocrea S, Riley DP, Caputi AP, et al. Antioxidant therapy: a new pharmacological approach in shock, inflammation and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135–59PubMedGoogle Scholar
  114. 114.
    Saliou C, Rimbach G, Moini H, et al. Solar UV induced erythema in human skin and nuclear factor-κB-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med 2001; 30: 154–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Faculty of PharmacyThe University of SydneySydneyAustralia

Personalised recommendations